ID: ALA5273774

Max Phase: Preclinical

Molecular Formula: C17H19BClNO3

Molecular Weight: 331.61

Associated Items:

Representations

Canonical SMILES:  CC(C)c1c(Oc2ccc(CN)cc2Cl)ccc2c1B(O)OC2

Standard InChI:  InChI=1S/C17H19BClNO3/c1-10(2)16-15(6-4-12-9-22-18(21)17(12)16)23-14-5-3-11(8-20)7-13(14)19/h3-7,10,21H,8-9,20H2,1-2H3

Standard InChI Key:  ZIIWGJMMDJWIKB-UHFFFAOYSA-N

Associated Targets(Human)

Rho-associated protein kinase 1 4723 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Rho-associated protein kinase 2 6206 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 331.61Molecular Weight (Monoisotopic): 331.1147AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Feng Y, LoGrasso PV, Defert O, Li R..  (2016)  Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.,  59  (6): [PMID:26486225] [10.1021/acs.jmedchem.5b00683]

Source